Prelude Therapeutics

Prelude Therapeutics is an American biopharmaceutical company. It develops and designs a pipeline of novel, orally bioavailable, and small molecule therapies that target key drivers of cancer cell growth. Prelude Therapeutics serves patients worldwide.
Prelude Therapeutics stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Prelude Therapeutics balance sheet

Report period20182019 2020 2021 2022 Q2 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Prelude Therapeutics cash flows

Report period20182019 2020 2021 2022 Q2 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Prelude Therapeutics multipliers

Report period20182019 2020 2021 2022 Q2 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Prelude Therapeutics profitability

Report period20182019 2020 2021 2022 Q2 23 TTM
ROA
ROE
ROS
Prelude Therapeutics assets
Prelude Therapeutics cash flows

Prelude Therapeutics dividend policy

The company doesn't provide dividend

Prelude Therapeutics shares

TickerNameTypeNominal valueISINPrice
PRLD:USPrelude TherapeuticsCommon share-US74065P1012$4.7
Prelude Therapeutics news
10.05.2022
Prelude Therapeutics' GAAP loss for 3 months of 2022 was $29.465 million, up 38.3% from $21.3 million in the previous year.
Source: {source} pictogram investors.preludetx.com
Pictogram next
16.03.2022
Prelude Therapeutics' GAAP loss for 2021 was $111.694 million, up 96.2% from $56.929 million the previous year.
Source: {source} pictogram investors.preludetx.com
Pictogram next
15.11.2021
Prelude Therapeutics' GAAP loss for 9M 2021 was $78.852 million, up 2.1 times from $37.679 million in the previous year.
Source: {source} pictogram investors.preludetx.com
Pictogram next
12.08.2021
Prelude Therapeutics' GAAP loss in Q2 2021 was $26.865 million, up 2.35 times from $11.408 million in the previous year.
Source: {source} pictogram investors.preludetx.com
Pictogram next
All Prelude Therapeutics news
General information
Company namePrelude Therapeutics
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address200 Powder Mill Road Wilmington, DE 19803 United States
Websiteinvestors.preludetx.com
Information disclosurewww.sec.gov